Lichtenstein GR, Sbreu MT, Cohen R, Tremaine W

Language: Spanish
References: 315
Page: 351-401
PDF size: 352.14 Kb.

Text Extraction

No abstract

REFERENCES

1. Crohn B, Ginzburg L, Oppenheimer GR. Regional ileitis. A pathologic and clinical entity. JAMA 1932; 99: 1323–29.

2. Wilks S, Moxon W. Lectures on pathological anatomy. 2nd ed. Philadelphia, PA: Lindsay and Blakiston; 1875.

3. Amsterdam A, Tajima K, Sasson R. Cell-specific regulation of apoptosis by glucocorticoids: implication to their antiinflammatory action. Biochem Pharmacol 2002; 64: 843–50.

4. Clark AR, Lasa M. Crosstalk between glucocorticoids and mitogen activated protein kinase signaling pathways. Curr Opin Pharmacol 2003; 3: 404-11.

5. Kagoshima M, Ito K, Cosio B, Adcock IM. Glucocorticoid suppression of nuclear factor-kappa B: a role for histone modifications. Biochem Soc Trans 2003; 31: 60-5.

6. De Bosscher K, Vanden Berghe W, Haegeman G. The interplay between the glucocorticoid receptor and nuclear factor-kappaB or activator protein-1: molecular mechanisms for gene repression. Endocr Rev 2003; 24: 488-522.

7. Hayashi R, Wada H, Ito K, Adcock IM. Effects of glucocorticoids on gene transcription. Eur J Pharmacol 2004; 500: 51-62.

8. Goulding NJ. The molecular complexity of glucocorticoid actions in inflammation-a four-ring circus. Curr Opin Pharmacol 2004; 4: 629-36.

9. Buttgereit F, Saag KG, Cutolo M, da Silva JA, Bijlsma JW. The molecular basis for the effectiveness, toxicity, and resistance to glucocorticoids: focus on the treatment of rheumatoid arthritis. Scand J Rheumatol 2005; 34: 14-21.

10. Scheinman RI, Cogswell PC, Lofquist AK, Baldwin AS Jr. Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids. Science 1995; 270: 283-86.

11. Tao Y, Williams-Skipp C, Scheinman RI. Mapping of glucocorticoid receptor DNA binding domain surfaces contributing to transrepression of NF-kappa B and induction of apoptosis. J Biol Chem 2001; 276: 2329-32.

12. Lofberg R, Danielsson A, Suhr O, Nilsson A, Schioler R, Nyberg A, Hultcrantz R, Kollberg B, Gillberg R, Willen R, Persson T, Salde L. Oral budesonide versus prednisolone in patients with active extensive and left-sided ulcerative colitis. Gastroenterology 1996; 110: 1713-18.

13. Bar-Meir S, Chowers Y, Lavy A, Lavy A, Abramovitch D, Sternberg A, Leichtmann G, Reshef R, Odes S, Moshkovitz M, Bruck R, Eliakim R, Maoz E, Mittmann U. Budesonide versus prednisone in the treatment of active Crohn’s disease. The Israeli Budesonide Study Group. Gastroenterology 1998; 115: 835-40.

14. Dahlberg E, Thalen A, Brattsand R, Gustafsson JA, Johansson U, Roempke K, Saartok T. Correlation between chemical structure, receptor binding, and biological activity of some novel, highly active, 16 alpha, 17 alpha-acetal-substituted glucocorticoids. Mol Pharmacol 1984; 25: 70-8.

15. Spencer CM, McTavish D. Budesonide. A review of its pharma-cological properties and therapeutic efficacy in inflammatory bowel disease. Drugs 1995; 50: 854-72.

16. Miller-Larsson A, Gustafson B, Persson CG, Brattsand R. Gut mucosal uptake and retention characteristics contribute to the high intestinal selectivity of budesonide compared with prednisolone in the rat. Aliment Pharmacol Ther 2001; 15: 2019-25.

17. Edsbacker S, Bengtsson B, Larsson P, Larsson P, Lundin P, Nilsson A, Ulmius J, Wollmer P. A Pharmacoscintigraphic evaluation of oral budesonide given as controlled release (Entocort) capsules. Aliment Pharmacol Ther 2003; 17: 525-36.

18. Lundin PD, Edsbacker S, Bergstrand M, Ejderhamn J, Linander H, Hogberg L, Persson T, Escher JC, Lindquist B. Pharmacokinetics of budesonide controlled ileal release capsules in children and adults with active Crohn’s disease. Aliment Pharmacol Ther 2003; 17: 85-92.

19. Greenberg GR, Feagan BG, Martin F, Martin F, Sutherland LR, Thomson AB, Williams CN, Nilsson LG, Persson T. Oral budesonide for active Crohn’s disease. Canadian Inflammatory Bowel Disease Study Group. N Engl J Med 1994; 331: 836-41.

20. Thomsen OO, Cortot A, Jewel D, Wright JP, Winter T, Veloso FT, Vatn M, Persson T, Pettersson E. A comparison of budesonide and mesalamine for active Crohn’s disease. International Budesonide-Mesalamine Study Group. N Engl J Med 1998; 339: 370-4.

21. Rutgeerts P, Lofberg R, Malchow H, Lamers C, Olaison G, Jewell D, Danielsson A, Goebell H, Thomsen OO, Lorenz-Meyer H, Hodgson H, Persson T, Seidegard C. A comparison of budesonide with prednisolone for active Crohn’s disease. N Engl J Med 1994; 331: 842-5.

22. Gross V, Andus T, Caesar I, Bischoff SC, Lochs H, Tromm A, Schulz HJ, Bar U, Weber A, Gierend M, Ewe K, Scholmerich J. Oral pH-modified release budesonide versus 6-methylpred-nisolone in active Crohn’s disease. German/Austrian Budesonide Study Group. Eur J Gastroenterol Hepatol 1996; 8: 905-9.

23. Campieri M, Ferguson A, Doe W, Persson T, Nilsson LG. Oral budesonide is as effective as oral prednisolone in active Crohn’s disease. The Global Budesonide Study Group. Gut 1997; 41: 209-14.

24. Kane SV, Schoenfeld P, Sandborn WJ, Tremaine W, Hofer T, Feagan BG. The effectiveness of budesonide therapy for Crohn’s disease. Aliment Pharmacol Ther 2002; 16: 1509-17.

25. Marshall JK, Irvine EJ. Rectal corticosteroids versus alternative treatments in ulcerative colitis: A meta-analysis. Gut 1997; 40: 775-81.

26. Cohen RD, Woseth DM, Thisted RA, Hanauer SB. A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am J Gastroenterol 2000; 95: 1263-76.

27. Mulder CJ, Fockens P, Meijer JW, van der Heide H, Wiltink EH, Tytgat GN. Beclomethasone dipropionate (3 mg) versus 5-aminosalicylic acid (2 g) versus the combination of both (3 mg/2 g) as retention enemas in active ulcerative proctitis. Eur J Gastroenterol Hepatol 1996; 8: 549-53.

28. Somerville KW, Langman MJ, Kane SP, MacGilchrist AJ, Watkinson G, Salmon P. Effect of treatment on symptoms and quality of life in patients with ulcerative colitis: Comparative trial of hydrocortisone acetate foam and prednisolone 21-phosphate enemas. (Clin Res Ed) Br Med J 1985; 291: 866.

29. Braverman DL, Lachmann EA, Nagler W. Avascular necrosis of bilateral knees secondary to corticosteroid enemas. Arch Phys Med Rehabil 1998; 79: 449–52.

30. Danielsson A, Hellers G, Lyrenas E, Lofberg R, Nilsson A, Olsson O, Olsson SA, Persson T, Salde L, Naesdal J. A controlled randomized trial of budesonide versus prednisolone retention enemas in active distal ulcerative colitis. Scand J Gastroenterol 1987; 22: 987-92.

31. The Danish Budesonide Study Group. Budesonide enema in distal ulcerative colitis. A randomized dose-response trial with prednisolone enema as positive control. Scand J Gastroenterol 1991; 26: 1225-30.

32. Lofberg R, Ostergaard Thomsen O, Langholz E, Langholz E, Schioler R, Danielsson A, Suhr O, Graffner H, Pahlman L, Matzen P, Moller-Petersen JF. Budesonide versus prednisolone retention enemas in active distal ulcerative colitis. Aliment Pharmacol Ther 1994; 8: 623–29.

33. Lemann M, Galian A, Rutgeerts P, Van Heuverzwijn R, Cortot A, Viteau JM, Elewaut A, Belaiche J, Froguel E, Modigliani R. Comparison of budesonide and 5-aminosalicylic acid enemas in active distal ulcerative colitis. Aliment Pharmacol Ther 1995; 9: 557-62.

34. Bianchi Porro G, Prantera C, Campieri M. Comparative trial of methylprednisolone and budesonide enemas in inactive distal ulcerative colitis. Eur J Gastroenterol Hepatol 1994; 6: 125-30.

35. Bar-Meir S, Fidder HH, Faszczyk M, Bianchi Porro G, Sturniolo GC, Mickisch O, Muller R, Greinwald R, Chowers Y, Grobeta V; International Budesonide Study Group. Budesonide foam vs. hydrocortisone acetate foam in the treatment of active ulcerative proctosigmoiditis. Dis Colon Rectum 2003; 46: 929-36.

36. Summers RW, Switz DM, Sessions JT Jr, Becktel JM, Best WR, Kern F Jr, Singleton JW. National Cooperative Crohn’s Disease Study: Results of drug treatment. Gastroenterology 1979; 77: 847-69.

37. Malchow H, Ewe K, Brandes JW, Goebell H, Ehms H, Sommer H, Jesdinsky H. European Cooperative Crohn’s Disease Study (ECCDS): Results of drug treatment. Gastroenterology 1984; 86: 249-66.

38. Modigliani R, Mary JY, Simon JF, Cortot A, Soule JC, Gendre JP, Rene E. Clinical, biological, and endoscopic picture of attacks of Crohn’s disease. Evolution on prednisolone. Groupe d’Etude Therapeutique des Affections Inflammatoires Digestives. Gastroenterology 1990; 98: 811-18.

39. Shaffer JA, Williams SE, Turnberg LA, Houston JB, Rowland M. Absorption of prednisolone in patients with Crohn’s disease. Gut 1983; 24:182-6.

40. Faubion WA Jr, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: A population-based study. Gastroenterology 2001; 121: 255-60.

41. Munkholm P, Langholz E, Davidsen M, Binder V. Frequency of glucocorticoid resistance and dependency in Crohn’s disease. Gut 1994; 35: 360-2.

42. Truelove SC, Witts LJ. Cortisone in ulcerative colitis; preliminary report on a therapeutic trial. Br Med J 1954; 4884: 375-8.

43. Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 1955; 4947: 1041-8.

44. Truelove SC, Watkinson G, Draper G. Comparison of corticosteroid and sulphasalazine therapy in ulcerative colitis. Br Med J 1962; 5321: 1708-11.

45. Van Hees PA, Van Lier HJ, Van Elteren PH, Driessen M, Van Hogezand RA, Ten Velde GP, Bakker JH, Van Tongeren JH. Effect of sulphasalazine in patients with active Crohn’s disease: A controlled double-blind study. Gut 1981; 22: 404-9.

46. Truelove SC, Willoughby CP, Lee EG, Kettlewell MG. Further experience in the treatment of severe attacks of ulcerative colitis. Lancet 1978; 2: 1086-8.

47. Truelove SC, Jewell DP. Intensive intravenous regimen for severe attacks of ulcerative colitis. Lancet 1974; 1: 1067-70.

48. Meyers S, Sachar DB, Goldberg JD, Janowitz HD. Corticotropin versus hydrocortisone in the intravenous treatment of ulcerative colitis. A prospective, randomized, double-blind clinical trial. Gastroenterology 1983; 85: 351-7.

49. Powell-Tuck J, Buckell NA, Lennard-Jones JE. A controlled comparison of corticotropin and hydrocortisone in the treatment of severe proc-tocolitis. Scand J Gastroenterol 1977; 12: 971-5.

50. Kaplan HP, Portnoy B, Binder HJ, Amatruda T, Spiro H. A controlled evaluation of intravenous adrenocorticotropic hormone and hydrocortisone in the treatment of acute colitis. Gastroenterology 1975; 69: 91-5.

51. Jarnerot G, Rolny P, Sandberg-Gertzen H. Intensive intravenous treatment of ulcerative colitis. Gastroenterology 1985; 89: 1005-13.

52. Shepherd HA, Barr GD, Jewell DP. Use of an intravenous steroid regimen in the treatment of acute Crohn’s disease. J Clin Gastroenterol 1986; 8: 154-9.

53. Chun A, Chadi RM, Korelitz BI, Colonna T, Felder JB, Jackson MH, Morgenstern EH, Rubin SD, Sacknoff AG, Gleim GM. Intravenous corticotrophin vs. hydrocortisone in the treatment of hospitalized patients with Crohn’s disease: A randomized double-blind study and follow-up. Inflamm Bowel Dis 1998; 4: 177-81.

54. Truelove SC, Witts LJ. Cortisone and corticotrophin in ulcerative colitis. Br Med J 1959; 34: 387-94.

55. Lennard-Jones JE, Mickiewicz JJ, Connell AM, Baron JH, Jones FA. Prednisone as maintenance treatment for ulcerative colitis in remission. Lancet 1965; 191: 188-9.

56. Powell-Tuck J, Bown RL, Chambers TJ, Lennard-Jones JE. A controlled trial of alternate day prednisolone as a maintenance treatment for ulcerative colitis in remission. Digestion 1981; 22: 263-70.

57. Greenberg GR, Feagan BG, Martin F, Sutherland LR, Thomson AB, Williams CN, Nilsson LG, Persson T. Oral budesonide as maintenance treatment for Crohn’s disease: A placebo controlled, dose ranging study. Canadian Inflammatory Bowel Disease Study Group. Gastroenterology 1996; 110: 45-51.

58. Lofberg R, Rutgeerts P, Malchow H, Lamers C, Danielsson A, Olaison G, Jewell D, Ostergaard Thomsen O, Lorenz-Meyer H, Goebell H, Hodgson H, Persson T, Seidegard C. Budesonide prolongs time to relapse in ileal and ileocaecal Crohn’s disease. A placebo controlled one year study. Gut 1996; 39: 82-6.

59. Ferguson A, Campieri M, Doe W, Persson T, Nygard G. Oral budesonide as maintenance therapy in Crohn’s disease-results of a 12 month study. Global Budesonide Study Group. Aliment Pharmacol Ther 1998; 12: 175-83.

60. Gross V, Andus T, Ecker KW, Raedler A, Loeschke K, Plauth M, Rasenack J, Weber A, Gierend M, Ewe K, Scholmerich J. Low dose oral pH modified release budesonide for maintenance of steroid induced remission in Crohn’s disease. The Budesonide Study Group. Gut 1998; 42: 493-6.

61. Hanauer S, Sandborn WJ, Persson A, Persson T. Budesonide as maintenance treatment in Crohn’s disease: A placebo controlled trial. Aliment Pharmacol Ther 2005; 21: 363-71.

62. Sandborn WJ, Lofberg R, Feagan BG, Hanauer SB, Campieri M, Greenberg GR, Budesonide for maintenance of remission in patients with Crohn’s disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials. Am J Gastroenterol 2005; 100: 1780-7.

63. Ewe K, Bottger T, Buhr HJ, Ecker KW, Otto HF. Low dose budesonide treatment for prevention of postoperative recurrence of Crohn’s disease: a multicentre randomized placebo controlled trial. German Budesonide Study Group. Eur J Gastroenterol Hepatol 1999; 11: 277-82.

64. Hellers G, Cortot A, Jewell D, Leijonmarck CE, Lofberg R, Malchow H, Nilsson LG, Pallone F, Pena S, Persson T, Prantera C, Rutgeerts P. Oral budesonide for prevention of postsurgical recurrence in Crohn’s disease. The IOIBD Budesonide Study Group. Gastroenterology 1999; 116: 294-300.

65. Mantzaris G, Petraki K, Chadioiordanides H, et al. Maintenance therapy with azathioprine is superior to budesonide in healing endoscopic lesions and improving histology in clinically quiescent Crohn’s disease (abstr). Gastroenterology 2002; 122: A-81.

66. Baron JH, Connell AM, Kanaghinis TG, Lennard-Jones JE, Jones AF. Out-patient treatment of ulcerative colitis. Comparison between three doses of oral prednisone. Br Med J 1962; 5302: 441-3.

67. Powell-Tuck J, Bown RL, Lennard-Jones JE. A comparison of oral pred-nisolone given as single or multiple daily doses for active proctocolitis. Scand J Gastroenterol 1978; 13: 833-37.

68. Berghouse LM, Elliott PR, Lennard-Jones JE, English J, Marks V. Plasma prednisolone levels during intravenous therapy in acute colitis. Gut 1982; 23: 980-83.

69. Landi B, Anh TN, Cortot A, Soule JC, Rene E, Gendre JP, Bories P, See A, Metman EH, Florent C. Endoscopic monitoring of Crohn’s disease treatment: A prospective, randomized clinical trial. The Groupe d’Etudes Therapeutiques des Affections Inflammatoires Digestives. Gastroenterology 1992; 102: 1647-53.

70. Modigliani R, Colombel JF, Dupas JL, Dapoigny M, Costil V, Veyrac M, Duclos B, Soule JC, Gendre JP, Galmiche JP, Danne O, Cadiot G, Lamouliatte H, Belaiche J, Mary JY. Mesalamine in Crohn’s disease with steroid induced remission: effect on steroid withdrawal and remission maintenance. Groupe d’Etudes Therapeutiques des Affections Inflammatoires Digestives. Gastroenterology 1996; 110: 688-93.

71. Brignola C, De Simone G, Iannone P, Belloli C, Evangelisti A, Campieri M, Belluzzi A, Gionchetti P, Tampieri M, Bertinelli E. Influence of steroid treatment’s duration in patients with active Crohn’s disease. Agents Actions 1992; Spec: C90-C92.

72. Cortot A, Colombel JF, Rutgeerts P, Lauritsen K, Malchow H, Hamling J, Winter T, Van Gossum A, Persson T, Pettersson E. Switch from systemic steroids to budesonide in steroid dependent patients with inactive Crohn’s disease. Gut 2001; 48: 186-90.

73. Singleton JW, Law DH, Kelley ML Jr, Mekhjian HS, Sturdevant RA. National Cooperative Crohn’s Disease Study: Adverse reactions to study drugs. Gastroenterology 1979; 77: 870-82.

74. Aberra FN, Lewis JD, Hass D, Rombeau JL, Osborne B, Lichtenstein GR. Corticosteroids and immunomodulators: postoperative infectious complication risk in inflammatory bowel disease patients. Gastroenterology 2003; 125: 320-7.

75. Bernstein CN, Leslie WD, Leboff MS. AGA technical review on osteoporosis in gastrointestinal diseases. Gastroenterology 2003; 124: 795-841.

76. Haderslev KV, Tjellesen L, Sorensen HA, Staun M. Alendronate increases lumbar spine bone mineral density in patients with Crohn’s disease. Gastroenterology 2000; 119: 639-46.

77. Clements D, Compston JE, Evans WD, Rhodes J. Hormone replacement therapy prevents bone loss in patients with inflammatory bowel disease. Gut 1993; 34: 1543-46.

78. Yang YX, Lichtenstein GR. Corticosteroids in Crohn’s disease. Am J Gastroenterol 2002; 97: 803-23.

79. Liu YF, Chen WM, Lin YF, Yang RC, Lin MW, Li LH, Chang YH, Jou YS, Lin PY, Su JS, Huang SF, Hsiao KJ, Fann CS, Hwang HW, Chen YT, Tsai SF. Type II collagen gene variants and inherited osteonecrosis of the femoral head. N Engl J Med 2005; 352: 2294-301.

80. Schoon EJ, Bollani S, Mills PR, Israeli E, Felsenberg D, Ljunghall S, Persson T, Hapten-White L, Graffner H, Bianchi Porro G, Vatn M, Stockbrugger RW. Matrix Study Group. Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn’s disease. Clin Gastroenterol Hepatol 2005; 3: 113-21.

81. Cooper MS, Stewart PM. Corticosteroid insufficiency in acutely ill patients. N Engl J Med 2003; 348: 727-34.

82. Lichtenstein GR. Use of laboratory testing to guide 6-mercaptopurine/azathioprine therapy. Gastroenterology 2004; 127: 1558-64.

83. Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol 1992; 43: 329-39.

84. Dubinsky MC, Lamothe S, Yang HY, Targan SR, Sinnett D, Theoret Y, Seidman EG. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000; 118: 705-13.

85. Cuffari C, Hunt S, Bayless T. Utilization of erythrocyte 6-thiogua-nine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease. Gut 2001; 48: 642-6.

86. Lowry PW, Franklin CL, Weaver AL, Pike MG, Mays DC, Tremaine WJ, Lipsky JJ, Sandborn WJ. Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease. Gut 2001; 49: 665-70.

87. Gupta P, Gokhale R, Kirschner BS. 6-mercaptopurine metabolite levels in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2001; 33: 450-4.

88. Aberra FN, Lichtenstein GR. Review article: monitoring of immunomodulators in inflammatory bowel disease. Aliment Pharmacol Ther 2005; 21: 307-19.

89. Dubinsky MC, Yang H, Hassard PV, Seidman EG, Kam LY, Abreu MT, Targan SR, Vasiliauskas EA. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 2002; 122: 904-15.

90. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyl transferase activity. Am J Hum Genet 1980; 32: 65-2.

91. Colombel JF, Ferrari N, Debuysere H, Marteau P, Gendre JP, Bonaz B, Soule JC, Modigliani R, Touze Y, Catala P, Libersa C, Broly F. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn’s disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000; 118: 1025-30.

92. Package insert for azathioprine/6-mercaptopurine. Imuran®, Prometheus Laboratories, Inc., San Diego, California, 2005.

93. Connell WR, Kamm MA, Dickson M, Balkwill AM, Ritchie JK, Lennard-Jones JE. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet 1994; 343: 1249-52.

94. Present DH, Meltzer SJ, Krumholz MP, Wolke A, Korelitz BI. 6-Mercaptopurine in the management of inflammatory bowel disease: short and long term toxicity. Ann Intern Med 1989; 111: 641-9.

95. Sandborn WJ. A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate. Am J Gastroenterol 1996; 91: 423-33.

96. Haber CJ, Meltzer SJ, Present DH, Korelitz BI. Nature and course of pancreatitis caused by 6-mercaptopurine in the treatment of inflammatory bowel disease. Gastroenterology 1986; 91: 982-6.

97. Korelitz BI, Zlatanic J, Goel F, Fuller S. Allergic reactions to 6-mercaptopurine during treatment of inflammatory bowel disease. J Clin Gastroenterol 1999; 28: 341-4.

98. Cheng B, Lichtenstein G. Are individuals with Crohn’s disease who are intolerant to 6-mercaptopurine able to tolerate azathioprine? (abstr). Gastroenterology 2000; 118: A1336.

99. Boulton-Jones JR, Pritchard K, Mahmoud AA. The use of 6-mercaptopurine in patients with inflammatory bowel disease after fai-lure of azathioprine therapy. Aliment Pharmacol Ther 2000; 14: 1561-5.

100. George J, Present DH, Pou R, Bodian C, Rubin PH. The longterm outcome of ulcerative colitis treated with 6-mercaptopurine. Am J Gastroenterol 1996; 91: 1711-14.

101. Korelitz BI, Fuller SR, Warman JI, Goldberg MD. Shingles during the course of treatment with 6-mercaptopurine for inflammatory bowel disease. Am J Gastroenterol 1999; 94: 424-6.

102. Pfau P, Kochman ML, Furth EE, Lichtenstein GR. Cytomegalovirus colitis complicating ulcerative colitis in the steroid-naive patient. Am J Gastroenterol 2001; 96: 895-99.

103. Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med 1995; 123: 132-42.

104. Lowry PW, Franklin CL, Weaver AL, Szumlanski CL, Mays DC, Loftus EV, Tremaine WJ, Lipsky JJ, Weinshilboum RM, Sandborn WJ. Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide. Gut 2001; 49: 656-64.

105. Szumlanski CL, Weinshilboum RM. Sulphasalazine inhibition of thiopurine methyltransferase: Possible mechanism for interaction with 6-mercaptopurine and azathioprine. Br J Clin Pharmacol 1995; 39: 456-9.

106. Lewis LD, Benin A, Szumlanski CL Otterness DM, Lennard L, Weinshilboum RM, Nierenberg DW. Olsalazine and 6-mercaptopurine related bone marrow suppression: A possible drug-drug interaction. Clin Pharmacol Ther 1997; 62: 464-75.

107. Gardiner S, Begg E, Barclay M, Kirkpatrick C. Genetic polymorphism and outcomes with azathioprine and 6-mercaptopurine. Adverse Drug React Toxicol Rev 2000; 19: 293-312.

108. Peppercorn MA. 6-mercaptopurine for the management of ulceractive colitis: a concept whose time has come. Am J Gastroenterol 1996; 91: 1689-90.

109. Lewis JD, Schwartz JS, Lichtenstein GR. Azathioprine for maintenance of remission in Crohn’s disease: benefits outweigh the risk of lymphoma. Gastroenterology 2000; 118: 1018-24.

110. Kandiel A, Fraser AG, Korelitz BI, Brensinger C, Lewis JD. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005; 54: 1121-5.

111. Winter J, Walker A, Shapiro D, Gaffney D, Spooner RJ, Mills PR. Cost-effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel disease. Aliment Pharmacol Ther 2004; 20: 593-9.

112. Black AJ, McLeod HL, Capell HA, Powrie RH, Matowe LK, Pritchard SC, Collie-Duguid ES, Reid DM. Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann Intern Med 1998; 129: 716-18.

113. Seddik M, Texier F, Ferrari N, et al. Thiopurine S-methyltransferase genotyping does not predict azathioprine-induced myelosuppression in Crohn’s disease (abstr). Gastroenterology 2003; 124: A311.

114. Curvers W, Derijks L, Stokkers P, et al. No predictive value of TPMT genotyping for leukopenia or hepatotoxicity during azathioprine therapy for inflammatory bowel disease (abstr). Gastroenterology 2003; 124: A377.

115. Sebbag L, Boucher P, Davelu P, Boissonnat P, Champsaur G, Ninet J, Dureau G, Obadia JF, Vallon JJ, Delaye J. Thiopurine S-methyltransferase gene polymorphism is predictive of azathioprine-induced myelosuppression in heart transplant recipients. Transplantation 2000; 69: 1524-7.

116. Kaskas BA, Louis E, Hindorf U, Schaeffeler E, Deflandre J, Graepler F, Schmiegelow K, Gregor M, Zanger UM, Eichelbaum M, Schwab M. Safe treatment of thiopurine S-methyltransferase deficient Crohn’s disease patients with azathioprine. Gut 2003; 52: 140-2.

117. Su C, Lichtenstein GR. Treatment of inflammatory bowel disease with azathioprine and 6-mercaptopurine. Gastroenterol Clin North Am 2004; 33: 209-34, viii.

118. Brooke BN, Hoffmann DC, Swarbrick ET. Azathioprine for Crohn’s disease. Lancet 1969; 2: 612-14.

119. Rhodes J, Bainton D, Beck P, Campbell H. Controlled trial of azathioprine in Crohn’s disease. Lancet 1971; 2: 1273-6.

120. Willoughby JM, Beckett J, Kumar PJ, Dawson AM. Controlled trial of azathioprine in Crohn’s disease. Lancet 1971; 2: 944-7.

121. Klein M, Binder HJ, Mitchell M, Aaronson R, Spiro H. Treatment of Crohn’s disease with azathioprine: A controlled evaluation. Gastroenterology 1974; 66: 916-22.

122. Present DH, Korelitz BI, Wisch N, Glass JL, Sachar DB, Pasternack BS. Treatment of Crohn’s disease with 6-mercaptopurine. A longterm, randomized, double-blind study. N Engl J Med 1980; 302: 981-7.

123. Ewe K, Press AG, Singe CC, Stufler M, Ueberschaer B, Hommel G, Meyer zum Buschenfelde KH. Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn’s disease. Gastroenterology 1993; 105: 367-72.

124. Candy S, Wright J, Gerber M, Adams G, Gerig M, Goodman R. A controlled double blind study of azathioprine in the management of Crohn’s disease. Gut 1995; 37: 674-8.

125. Oren R, Moshkowitz M, Odes S, Becker S, Keter D, Pomeranz I, Shirin C, Reisfeld I, Broide E, Lavy A, Fich A, Eliakim R, Patz J, Villa Y, Arber N, Gilat T. Methotrexate in chronic active Crohn’s disease: A double-blind, randomized, Israeli multicenter trial. Am J Gastroenterol 1997; 92: 2203-9.

126. Hawthorne AB, Logan RF, Hawkey CJ, Foster PN, Axon AT, Swarbrick ET, Scott BB, Lennard-Jones JE. Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. BMJ 1992; 305: 20-2.

127. Jewell DP, Truelove SC. Azathioprine in ulcerative colitis: final report on controlled therapeutic trial. Br Med J 1974; 4: 627-30.

128. Rosenberg JL, Wall AJ, Levin B, Binder HJ, Kirsner JB. A controlled trial of azathioprine in the management of chronic ulcerative colitis. Gastroenterology 1975; 69: 96-9.

129. Kirk AP, Lennard-Jones JE. Controlled trial of azathioprine in chronic ulcerative colitis. Br Med J (Clin Res Ed) 1982; 284: 1291-2.

130. Caprilli R, Carratu R, Babbini M. Double-blind comparison of the effectiveness of azathioprine and sulfasalazine in idiopathic proctocolitis. Preliminary report. Am J Dig Dis 1975; 20: 115-20.

131. Ardizzone S, Samolvico F, Bollani S, Imbesi V, Colombo E, Bianchi P G. Azathioprine is more effective than oral 5-ASA in the treatment of steroid dependent ulcerative colitis (abstr). Gastroenterology 2001; 120: A127.

132. Mantzaris GJ, Sfakianakis M, Archavlis E, Petraki K, Christidou A, Karagiannidis A, Triadaphyllou G. A prospective randomized observer-blind 2-year trial of azathioprine monotherapy versus azathioprine and olsalazine for the maintenance of remission of steroid dependent ulcerative colitis. Am J Gastroenterol 2004; 99: 1122-8.

133. Sood A, Midha V, Sood N, Kaushal V. Role of azathioprine in severe ulcerative colitis: one-year, placebo controlled, randomized trial. Indian J Gastroenterol 2000; 19: 14-16.

134. Cohen RD, Stein R, Hanauer SB. Intravenous cyclosporin in ulcerative colitis: A five-year experience. Am J Gastroenterol 1999; 94: 1587-92.

135. Fernández-Banares F, Bertran X, Esteve-Comas M, Cabre E, Menacho M, Humbert P, Planas R, Gassull MA. Azathioprine is useful in maintaining long term remission induced by intravenous cyclosporine in steroid-refractory severe ulcerative colitis. Am J Gastroenterol 1996; 91: 2498-9.

136. Domenech E, García-Planella E, Bernal I, Rosinach M, Cabre E, Fluvia L, Boix J, Gassull MA. Azathioprine without oral cyclosporin in the long term maintenance of remission induced by intravenous cyclosporin in severe, steroid refractory ulcerative colitis. Aliment Pharmacol Ther 2002; 16: 2061-5.

137. Markowitz J, Grancher K, Kohn N, Lesser M, Daum F. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn’s disease. Gastroenterology 2000; 119: 895-902.

138. Rosenberg JL, Levin B, Wall AJ, Kirsner JB. A controlled trial of azathioprine in Crohn’s disease. Am J Dig Dis 1975; 20: 721-6.

139. O’Donoghue DP, Dawson AM, Powell-Tuck J, Brown RL, Lennard-Jones JE. Double-blind withdrawal trial of azathioprine as main-tenance treatment for Crohn’s disease. Lancet 1978; 2: 955-7.

140. Achkar JP, Hanauer SB. Medical therapy to reduce postoperative Crohn’s disease recurrence. Am J Gastroenterol 2000; 95: 1139-46.

141. Olaison G, Smedh K, Sjodahl R. Natural course of Crohn’s disease after ileocolic resection: Endoscopically visualised ileal ulcers preceding symptoms. Gut 1992; 33: 331-5.

142. Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hiele M. Predictability of the postoperative course of Crohn’s disease. Gastroenterology 1990; 99: 956-63.

143. Lautenbach E, Berlin JA, Lichtenstein GR. Risk factors for early postoperative recurrence of Crohn’s disease. Gastroenterology 1998; 115: 259-67.

144. Rutgeerts P, Hiele M, Geboes K, Peeters M, Penninckx F, Aerts R, Kerremans R. Controlled trial of metronidazole treatment for prevention of Crohn’s recurrence after ileal resection. Gastroenterology 1995; 108: 1617-21.

145. Rutgeerts P, Van Assche G, Vermeire S, D’Haens G, Baert F, Noman M, Aerden I, De Hertogh G, Geboes K, Hiele M, D’Hoore A, Penninckx F. Ornidazole for prophylaxis of postoperative Crohn’s disease recurrence: A randomized, double-blind, placebo controlled trial. Gastroenterology 2005;128: 856-61.

146. Hanauer SB, Korelitz BI, Rutgeerts P, Peppercorn MA, Thisted RA, Cohen RD, Present DH. Postoperative maintenance of Crohn’s disease remission with 6-mercaptopurine, mesalamine, or placebo: A 2-year trial. Gastroenterology 2004; 127: 723-9.

147. Sandborn WJ, Feagan BG. The efficacy of azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in patients with Crohn’s disease remains uncertain. Gastroenterology 2004; 127: 990-3.

148. Ardizzone S, Maconi G, Sampietro GM, Russo A, Radice E, Colombo E, Imbesi V, Molteni M, Danelli PG, Taschieri AM, Bianchi Porro G. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn’s disease. Gastroenterology 2004; 127: 730-40.

149. Hanauer S, Cohen R, Thisted R, Rutgeerts P, Present D, Korelitz B. Reply to: 6-mercaptopurine and mesalamine for prevention of relapse after conservative therapy for Crohn’s disease (letter). Gastroenterology 2005; 128: 249-51.

150. Feagan BG, Rochon J, Fedorak RN, Irvine JE, Wild G, Sutherland L, Steinhart AH, Greenberg GR, Gillies R, Hopkins M, Hanauer SB, McDonald JWD. Methotrexate for the treatment of Crohn’s disease. The North American Crohn’s Study Group Investigators. N Engl J Med 1995; 332: 292-7.

151. Oren R, Arber N, Odes S, Moshkowitz M, Keter D, Pomeranz I, Ron Y, Reisfeld I, Broide E, Lavy A, Fich A, Eliakim R, Patz J, Bardan E, Villa Y, Gilat T. Methotrexate in chronic active ulcerative colitis: A double-blind, randomized, Israeli multicenter trial. Gastroenterology 1996; 110: 1416-21.

152. Arora S, Katkov W, Cooley J, Kemp JA, Johnston DE, Schapiro RH, Podolsky D. Methotrexate in Crohn’s disease: results of a randomized, double-blind, placebo controlled trial. Hepatogastroenterology 1999; 46: 1724-9.

153. Feagan BG, Fedorak RN, Irvine EJ, Sutherland L, Steinhart AH, Greenberg GR, Koval J, Wong CJ, Hopkins M, Hanauer SB, McDonald JW. A comparison of methotrexate with placebo for the maintenance of remission in Crohn’s disease. North American Crohn’s Study Group Investigators. N Engl J Med 2000; 342: 1627-32.

154. Chong RY, Hanauer SB, Cohen RD. Efficacy of parenteral methotrexate in refractory Crohn’s disease. Aliment Pharmacol Ther 2001; 15: 35-44.

155. Fraser G, Ben-Bassat O, Segal N, Fishman-Mor M, Niv Y. Parenteral methotrexate is not effective treatment for refractory ulcerative colitis. Gastroenterology 2003; 124 (Suppl. 1); A525.

156. Cummings JR, Herrlinger KR, Travis SP, Gorard DA, McIntyre AS, Jewell DP. Oral methotrexate in ulcerative colitis. Aliment Pharmacol Ther 2005; 21: 385-9.

157. Mahadevan U, Marion JF, Present DH. Fistula response to methotrexate in Crohn’s disease: A case series. Aliment Pharmacol Ther 2003; 18: 1003-8.

158. Vandeputte L, D’Haens G, Baert F, Rutgeerts P. Methotrexate in refractory Crohn’s disease. Inflamm Bowel Dis 1999; 5: 11-15.

159. Campbell MS, Reddy KR. Review article: the evolving role of liverbiopsy. Aliment Pharmacol Ther 2004; 20: 249-59.

160. Kozarek R, Brefeldt J, Rosoff L, Patterson D, Fenster L. Does methotrexate (MTX) cause liver toxicity when used for refractory inflammatory bowel disease (IBD)? (abstr). Gastroenterology 1991; 100: A221.

161. Te HS, Schiano TD, Kuan SF, Hanauer SB, Conjeevaram HS, Baker AL. Hepatic effects of longterm methotrexate use in the treatment of inflammatory bowel disease. Am J Gastroenterol 2000; 95: 3150-56.

162. Kremer JM, Alarcon GS, Lightfoot RW Jr, Willkens RF, Furst DE, Williams HJ, Dent PB, Weinblatt ME. Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology. Arthritis Rheum 1994; 37: 316-28.

163. Kremer JM, Galivan J, Streckfuss A, Kamen B. Methotrexate metabolism analysis in blood and liver of rheumatoid arthritis patients. Association with hepatic folate deficiency and formation of polyglutamates. Arthritis Rheum 1986; 29: 832-5.

164. Schilsky RL, Lewis BJ, Sherins RJ, Young RC. Gonadal dysfunction in patients receiving chemotherapy for cancer. Ann Intern Med 1980; 93: 109-14.

165. Rustin GJ, Booth M, Dent J, Salt S, Rustin F, Bagshawe KD. Pregnancy after cytotoxic chemotherapy for gestational trophoblastic tumours. Br Med J (Clin Res Ed) 1984; 288: 103-6.

166. Weissbach L, Lange CE, Rodermund OE, Zwicker H, Gropp A, Pothmann W. [Fertility disturbances following treatment of patients with testicular tumors (author’s transl)]. Urologe A 1974; 13: 80-5.

167. Hinkes E, Plotkin D. Reversible drug-induced sterility in a patient with acute leukemia. JAMA 1973; 223: 1490-1.

168. Sussman A, Leonard JM. Psoriasis, methotrexate, and oligospermia. Arch Dermatol 1980; 116: 215-17.

169. Milunsky A, Graef JW, Gaynor MF Jr. Methotrexate induced congenital malformations. J Pediatr 1968; 72: 790-5.

170. Powell HR, Ekert H. Methotrexate induced congenital malformations. Med J Aust 1971; 2: 1076-7.

171. Pizzuto J, Aviles A, Noriega L, Niz J, Morales M, Romero F. Treatment of acute leukemia during pregnancy: Presentation of nine cases. Cancer Treat Rep 1980; 64: 679-83.

172. Okun DB, Groncy PK, Sieger L, Tanaka KR. Acute leukemia in pregnancy: transient neonatal myelosuppression after combination chemotherapy in the mother. Med Pediatr Oncol 1979; 7: 315-19.

173. Briggs G, Freeman R, Yaffe S. Drugs in pregnancy and lactation. 5th ed. Baltimore, MD: Williams and Wilkins; 1998.

174. American Academy of Pediatrics Committee on Drugs. The transfer of drugs and other chemicals into human milk. Pediatrics 1994; 93: 137-50.

175. Kitchin JE, Pomeranz MK, Pak G, Washenik K, Shupack JL. Rediscovering mycophenolic acid: a review of its mechanism, side effects, and potential uses. J Am Acad Dermatol 1997; 37: 445-9.

176. Fickert P, Hinterleitner TA, Wenzl HH, Aichbichler BW, Petritsch W. Mycophenolate mofetil in patients with Crohn’s disease. Am J Gastroenterol 1998; 93: 2529-32.

177. Neurath MF, Wanitschke R, Peters M, Krummenauer F, Meyer zum Buschenfelde KH, Schlaak JF. Randomised trial of mycophenolate mofetil versus azathioprine for treatment of chronic active Crohn’s disease. Gut 1999; 44: 625-8.

178. Orth T, Peters M, Schlaak JF, Krummenauer F, Wanitschke R, Mayet WJ, Galle PR, Neurath MF. Mycophenolate mofetil versus azathioprine in patients with chronic active ulcerative colitis: A 12 month pilot study. Am J Gastroenterol 2000; 95: 1201-7.

179. Hassard PV, Vasiliauskas EA, Kam LY, Targan SR, Abreu MT. Efficacy of mycophenolate mofetil in patients failing 6-mercaptopurine or azathioprine therapy for Crohn’s disease. Inflamm Bowel Dis 2000; 6: 16-20.

180. Fellermann K, Steffen M, Stein J, Raedler A, Hamling J, Ludwig D, Loeschke K, Stange EF. Mycophenolate mofetil: lack of efficacy in chronic active inflammatory bowel disease. Aliment Pharmacol Ther 2000; 14: 171-6.

181. Miehsler W, Reinisch W, Moser G, Gangl A, Vogelsang H. Is mycophenolate mofetil an effective alternative in azathioprine intolerant patients with chronic active Crohn’s disease? Am J Gastroenterol 2001; 96: 782-7.

182. Hafraoui S, Dewit O, Marteau P, Cosnes J, Colombel JF, Modigliani R, Cortot A, Lemann M. [Mycophenolate mofetil in refractory Crohn’s disease after failure of treatments by azathioprine or methotrexate.] Gastroenterol Clin Biol 2002; 26: 17-22.

183. Skelly MM, Logan RF, Jenkins D, Mahida YR, Hawkey CJ. Toxicity of mycophenolate mofetil in patients with inflammatory bowel disease. Inflamm Bowel Dis 2002; 8: 93-7.

184. Papadimitriou JC, Cangro CB, Lustberg A, Khaled A, Nogueira J, Wiland A, Ramos E, Klassen DK, Drachenberg CB. Histologic features of mycophenolate mofetil-related colitis: A graft-versus-host disease like pattern. Int J Surg Pathol 2003; 11: 295-302.

185. Dalle IJ, Maes BD, Geboes KP, Lemahieu W, Geboes K. Crohn’s-like changes in the colon due to mycophenolate? Colorectal Dis 2005; 7: 27-34.

186. Borel JF, Feurer C, Gubler HU, Stahelin H. Biological effects of cyclosporin A: a new antilymphocytic agent. Agents Actions 1976; 6: 468-75.

187. Liu J, Farmer JD Jr, Lane WS, Friedman J, Weissman I, Schreiber SL. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 1991; 66: 807-15.

188. Schreiber SL, Crabtree GR. The mechanism of action of cyclosporin A and FK506. Immunol Today 1992; 13: 136-42.

189. Gupta S, Keshavarzian A, Hodgson HJ. Cyclosporin in ulcerative colitis. Lancet 1984; 2: 1277-78.

190. Hyams JS, Treem WR. Cyclosporine treatment of fulminant colitis. J Pediatr Gastroenterol Nutr 1989; 9: 383-7.

191. Lichtiger S, Present DH. Preliminary report: Cyclosporin in treatment of severe active ulcerative colitis. Lancet 1990; 336: 16-19.

192. Porro GB, Petrillo M, Ardizzone S. Cyclosporin treatment for severe active ulcerative colitis. Lancet 1990; 336: 439.

193. Lichtiger S, Present DH, Kornbluth A, Gelernt I, Bauer J, Galler G, Michelassi F, Hanauer S. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994; 330: 1841-5.

194. Santos J, Baudet S, Casellas F, Guarner L, Vilaseca J, Malagelada JR. Efficacy of intravenous cyclosporine for steroid refractory attacks of ulcerative colitis. J Clin Gastroenterol 1995; 20: 285-9.

195. Treem WR, Cohen J, Davis PM, Justinich CJ, Hyams JS. Cyclosporine for the treatment of fulminant ulcerative colitis in children. Immediate response, longterm results, and impact on surgery. Dis Colon Rectum 1995; 38: 474-9.

196. Kornbluth A, Lichtiger S, Present D, Hanauer S. Longterm results of oral cyclosporine in patients with severe ulcerative colitis: A double-blind, randomized, multicenter trial (abstr). Gastroenterology 1994; 106: A714.

197. Carbonnel F, Boruchowicz A, Duclos B, Soule JC, Lerebours E, Lemann M, Belaiche J, Colombel JF, Cosnes J, Gendre JP. Intravenous cyclosporine in attacks of ulcerative colitis: short-term and longterm responses. Dig Dis Sci 1996; 41: 2471-6.

198. Van Gossum A, Schmit A, Adler M, Chioccioli C, Fiasse R, Louwagie P, D’Haens G, Rutgeerts P, De Vos M, Reynaert H, Devis G, Belaiche J, Van Outryve M. Short and longterm efficacy of cyclosporin administration in patients with acute severe ulcerative colitis. Belgian IBD Group. Acta Gastroenterol Belg 1997; 60: 197-200.

199. Kornbluth A, Present DH, Lichtiger S, Hanauer S. Cyclosporin for severe ulcerative colitis: A user’s guide. Am J Gastroenterol 1997; 92: 1424-8.

200. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2004; 99: 1371-85.

201. Smith MB, Hanauer SB. Pneumocystis carinii pneumonia during cyclosporine therapy for ulcerative colitis. N Engl J Med 1992; 327: 497-8.

202. Sandborn W. A critical review of cyclosporine therapy in inflammatory bowel disease. Inflamm Bowel Dis 1995; 1: 48-63.

203. Schutz E, Svinarov D, Shipkova M, Niedmann PD, Armstrong VW, Wieland E, Oellerich M. Cyclosporin whole blood immunoassays (AxSYM, CEDIA, and Emit): a critical overview of performance characteristics and comparison with HPLC. Clin Chem 1998; 44: 2158-64.

204. Vermeire S, Rutgeerts P. Cyclosporine monotherapy is effective in the treatment of severe ulcerative colitis. Inflamm Bowel Dis 1996; 2: 253-4.

205. D’Haens G, Lemmens L, Geboes K, Vandeputte L, Van Acker F, Mortelmans L, Peeters M, Vermeire S, Penninckx F, Nevens F, Hiele M, Rutgeerts P. Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology 2001; 120: 1323-9.

206. Cohen RD. Intravenous cyclosporine in severe ulcerative colitis: ready to stand alone? Gastroenterology 2001; 120: 1541-3.

207. Van Assche G, D’Haens G, Noman M, Vermeire S, Hiele M, Asnong K, Arts J, D’Hoore A, Penninckx F, Rutgeerts P. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology 2003; 125: 1025-31.

208. Allam BF, Tillman JE, Thomson TJ, Crossling FT, Gilbert LM. Effective intravenous cyclosporin therapy in a patient with severe Crohn’s disease on parenteral nutrition. Gut 1987; 28: 1166-9.

209. Lobo AJ, Juby LD, Rothwell J, Poole TW, Axon AT. Longterm treatment of Crohn’s disease with cyclosporine: The effect of a very low dose on maintenance of remission. J Clin Gastroenterol 1991; 13: 42-5.

210. Lichtiger S. Cyclosporine therapy in inflammatory bowel disease: open label experience. Mt Sinai J Med 1990; 57: 315-19.

211. Mahdi G, Israel DM, Hassall E. Cyclosporine and 6-mercaptopurine for active, refractory Crohn’s colitis in children. Am J Gastroenterol 1996; 91: 1355-9.

212. Egan LJ, Sandborn WJ, Tremaine WJ. Clinical outcome following treatment of refractory inflammatory and fistulizing Crohn’s disease with intravenous cyclosporine. Am J Gastroenterol 1998; 93: 442-8.

213. Present DH, Lichtiger S. Efficacy of cyclosporine in treatment of fistula of Crohn’s disease. Dig Dis Sci 1994; 39: 374-80.

214. Hinterleitner TA, Petritsch W, Aichbichler B, Fickert P, Ranner G, Krejs GJ. Combination of cyclosporine, azathioprine and prednisolone for perianal fistulas in Crohn’s disease. Z Gastroenterol 1997; 35: 603-8.

215. Judge TA, Lichtenstein GR. Treatment of fistulizing Crohn’s disease. Gastroenterol Clin North Am 2004; 33: 421-54, xi-xii.

216. Drewe J, Meier R, Vonderscher J, Kiss D, Posanski U, Kissel T, Gyr K. Enhancement of the oral absorption of cyclosporin in man. Br J Clin Pharmacol 1992; 34: 60-4.

217. Mueller EA, Kovarik JM, van Bree JB, Tetzloff W, Grevel J, Kutz K. Improved dose linearity of cyclosporine pharmacokinetics from a microemulsion formulation. Pharm Res 1994; 11: 301-4.

218. Kovarik JM, Mueller EA, Johnston A, Hitzenberger G, Kutz K. Bioequivalence of soft gelatin capsules and oral solution of a new cyclosporine formulation. Pharmacotherapy 1993; 13: 61317.

219. Frei UA, Neumayer HH, Buchholz B, Niese D, Mueller EA. Randomized, double-blind, one year study of the safety and tolerability of cyclosporine microemulsion compared with conventional cyclosporine in renal transplant patients. International Sandimmun Neoral Study Group. Transplantation 1998; 65: 1455-60.

220. Actis GC, Aimo G, Priolo G, Moscato D, Rizzetto M, Pagni R. Efficacy and efficiency of oral microemulsion cyclosporin versus intravenous and soft gelatin capsule cyclosporin in the treatment of severe steroid refractory ulcerative colitis: An open label retrospective trial. Inflamm Bowel Dis 1998; 4: 276-9.

221. Actis GC, Volpes R, Rizzetto M. Oral microemulsion cyclosporin to reduce steroids rapidly in chronic active ulcerative colitis. Eur J Gastroenterol Hepatol 1999; 11: 905-8.

222. Navazo L, Salata H, Morales S, Dorta MC, Perez F, de las Casas D, Aviles J. Oral microemulsion cyclosporine in the treatment of steroid-refractory attacks of ulcerative and indeterminate colitis. Scand J Gastroenterol 2001; 36: 610-14.

223. Brynskov J, Freund L, Rasmussen SN, Lauritsen K, de Muck-adell OS, Williams N, MacDonald AS, Tanton R, Molina F, Campanini MC. A placebo controlled, double-blind, randomized trial of cyclosporine therapy in active chronic Crohn’s disease. N Engl J Med 1989; 321: 845-50.

224. Brynskov J, Freund L, Norby Rasmussen S, Rasmussen S, Lauritsen K, Schaffalitzky de Muckadell O, Williams CN, Mac-Donald AS, Tanton R, Molina F, Campanini MC, et al. Final report on a placebo controlled, double-blind, randomized, multicentre trial of cyclosporin treatment in active chronic Crohn’s disease. Scand J Gastroenterol 1991; 26: 689-95.

225. Jewell DP, Lennard-Jones JE. Oral cyclosporine for chronic active Crohn’s disease: A multicentre controlled trial. Eur J Gastroenterol Hepatol 1994; 6: 499-505.

226. Feagan BG, McDonald JW, Rochon J, Laupacis A, Fedorak RN, Kinnear D, Saibil F, Groll A, Archambault A, Gillies R, Valberg B, Irvine EJ. Lowdose cyclosporine for the treatment of Crohn’s disease. The Canadian Crohn’s Relapse Prevention Trial Investigators. N Engl J Med 1994; 330: 1846-51.

227. Stange EF, Modigliani R, Pena AS, Wood AJ, Feutren G, Smith PR. European trial of cyclosporine in chronic active Crohn’s disease: A 12 month study. The European Study Group. Gastroenterology 1995; 109: 774-82.

228. Feagan BG, McDonald JW. Cyclosporin in Crohn’s disease. Lancet 1997; 349: 1328.

229. McDonald JW, Feagan BG, Jewell D, Brynskov J, Stange EF, Macdonald JK. Cyclosporine for induction of remission in Crohn’s disease. Cochrane Database Syst Rev 2005; 2: CD000297.

230. Brynskov J, Freund L, Thomsen OO, Andersen CB, Rasmussen SN, Binder V. Treatment of refractory ulcerative colitis with cyclosporin enemas. Lancet 1989; 1: 721-2.

231. Ranzi T, Campanini MC, Velio P, Quarto di Palo F, Bianchi P. Treatment of chronic proctosigmoiditis with cyclosporin enemas. Lancet 1989; 2: 97.

232. Sandborn WJ, Tremaine WJ, Schroeder KW, Steiner BL, Batts KP, Lawson GM. Cyclosporine enemas for treatment resistant, mildly to moderately active, left-sided ulcerative colitis. Am J Gastroenterol 1993; 88: 640-5.

233. Winter TA, Dalton HR, Merrett MN, Campbell A, Jewell DP. Cyclosporin A retention enemas in refractory distal ulcerative colitis and “pouchitis.” Scand J Gastroenterol 1993; 28: 701-4.

234. Sandborn WJ, Tremaine WJ, Schroeder KW, Batts KP, Lawson GM, Steiner BL, Harrison JM, Zinsmeister AR. A placebo controlled trial of cyclosporine enemas for mildly to moderately active left sided ulcerative colitis. Gastroenterology 1994; 106: 1429-35.

235. Flanagan WM, Corthesy B, Bram RJ, Crabtree GR. Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A. Nature 1991; 352: 803-7.

236. Bousvaros A, Kirschner BS, Werlin SL, Parker-Hartigan L, Daum F, Freeman KB, Balint JP, Day AS, Griffiths AM, Zurakowski D, Ferry GD, Leichtner AM. Oral tacrolimus treatment of severe colitis in children. J Pediatr 2000; 137: 794-9.

237. Fellermann K, Tanko Z, Herrlinger KR, Witthoeft T, Homann N, Bruening A, Ludwig D, Stange EF. Response of refractory colitis to intravenous or oral tacrolimus (FK506). Inflamm Bowel Dis 2002; 8: 317-24.

238. Hogenauer C, Wenzl HH, Hinterleitner TA, Petritsch W. Effect of oral tacrolimus (FK 506) on steroid refractory moderate/severe ulcerative colitis. Aliment Pharmacol Ther 2003; 18: 415-23.

239. Lowry PW, Weaver AL, Tremaine WJ, Sandborn WJ. Combination therapy with oral tacrolimus (FK506) and azathioprine or 6-mer-captopurine for treatment refractory Crohn’s disease perianal fistulae. Inflamm Bowel Dis 1999; 5: 239-45.

240. Ierardi E, Principi M, Rendina M, Francavilla R, Ingrosso M, Pisani A, Amoruso A, Panella C, Francavilla A. Oral tacrolimus (FK 506) in Crohn’s disease complicated by fistulae of the perineum. J Clin Gastroenterol 2000; 30: 200-2.

241. Sandborn WJ, Present DH, Isaacs KL, Wolf DC, Greenberg E, Hanauer SB, Feagan BG, Mayer L, Johnson T, Galanko J, Martin C, Sandler RS. Tacrolimus for the treatment of fistulas in patients with Crohn’s disease: A randomized, placebo-controlled trial. Gastroenterology 2003; 125: 380-8.

242. Van Deventer SJ. Tumour necrosis factor and Crohn’s disease. Gut 1997; 40: 443-8.

243. Physician’s Desk Reference. 59th ed. Montvale, NJ: Medical Economics Co; 2005.

244. Physician’s Desk Reference. 58th ed. Montvale, NJ: Medical Economics Co; 2004.

245. van Dullemen HM, van Deventer SJ, Hommes DW, Bijl HA, Jansen J, Tytgat GN, Woody J. Treatment of Crohn’s disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995; 109: 129-35.

246. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, DeWoody KL, Schaible TF, Rutgeerts PJ. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group. N Engl J Med 1997; 337: 1029-35.

247. Rutgeerts P, D’Haens G, Targan S, Vasiliauskas E, Hanauer SB, Present DH, Mayer L, Van Hogezand RA, Braakman T, DeWoody KL, Schaible TF, Van Deventer SJ. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn’s disease. Gastroenterology 1999; 117: 761-9.

248. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Rutgeerts P; ACCENT I Study Group. Maintenance infliximab for Crohn’s disease: The ACCENT I randomised trial. Lancet 2002; 359: 1541-9.

249. Rutgeerts P, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Hanauer SB. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease. Gastroenterology 2004; 126: 402-13.

250. Sartor RB. Episodic retreatment versus scheduled maintenance therapy of Crohn’s disease with infliximab: not so far apart. Gastroenterology 2004; 126: 598-601.

251. Baert F, Noman M, Vermeire S, Van Assche G, D’ Haens G, Carbonez A, Rutgeerts P. Influence of immunogenicity on the long term efficacy of infliximab in Crohn’s disease. N Engl J Med 2003; 348: 601-8.

252. Hanauer SB, Wagner CL, Bala M, Mayer L, Travers S, Diamond RH, Olson A, Bao W, Rutgeerts P. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn’s disease. Clin Gastroenterol Hepatol 2004; 2: 542-53.

253. Farrell RJ, Alsahli M, Jeen YT, Falchuk KR, Peppercorn MA, Michetti P. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn’s disease: A randomized controlled trial. Gastroenterology 2003; 124: 917-24.

254. Sandborn WJ. Preventing antibodies to infliximab in patients with Crohn’s disease: Optimize not immunize. Gastroenterology 2003; 124: 1140-5.

255. Lemann M, Colombel J, Duclos B, Veyrac M, Dupas J, Delchier J, Laharie D, Moreau J, Dadiot G, Sobhani I, Metman E, Boureille A. Infliximab in steroid dependent Crohn’s Disease patients treated with azathioprine or 6-MP: A randomized double- blind placebo controlled trial (abstr). Gut 203; 52 (Suppl.): A44.

256. Hochberg MC, Tracy JK, Hawkins-Holt M, Flores RH. Comparison of the efficacy of the tumour necrosis factor alpha blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis. Ann Rheum Dis 2003; 62(Suppl. 2): 13-16.

257. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, Podolsky DK, Sands BE, Braakman T, DeWoody KL, Schaible TF, van Deventer SJ. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med 1999; 340: 1398-405.

258. Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, Kamm MA, Korzenik JR, Lashner BA, Onken JE, Rachmilewitz D, Rutgeerts P, Wild G, Wolf DC, Marsters PA, Travers SB, Blank MA, van Deventer SJ. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med 2004; 350: 876-85.

259. van Bodegraven AA, Sloots CE, Felt-Bersma RJ, Meuwissen SG. Endosonographic evidence of persistence of Crohn’s disease associated fistulas after infliximab treatment, irrespective of clinical response. Dis Colon Rectum 2002; 45: 39-45; discussion 46.

260. Van Assche G, Vanbeckevoort D, Bielen D, Coremans G, Aerden I, Noman M, D’Hoore A, Penninckx F, Marchal G, Cornillie F, Rutgeerts P. Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn’s disease. Am J Gastroenterol 2003; 98: 332-9.

261. Poritz LS, Rowe WA, Koltun WA. Remicade does not abolish the need for surgery in fistulizing Crohn’s disease. Dis Colon Rectum 2002; 45: 771-5.

262. Sands BE, Blank MA, Patel K, van Deventer SJ. Longterm treatment of rectovaginal fistulas in Crohn’s disease: response to infliximab in the ACCENT II Study. Clin Gastroenterol Hepatol 2004; 2: 912-20.

263. Levy C, Tremaine WJ. Management of internal fistulas in Crohn’s disease. Inflamm Bowel Dis 2002; 8: 106-11.

264. Sands BE, Tremaine WJ, Sandborn WJ, Rutgeerts PJ, Hanauer SB, Mayer L, Targan SR, Podolsky DK. Infliximab in the treatment of severe, steroid refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis 2001; 7: 83-8.

265. Rutgeerts P, Feagan B, Olson A, Johanns J, Travers S, Present D, Sands BE, Sandborn W, Olson A. A randomized placebo-controlled trial of infliximab therapy for active ulcerative colitis: Act I trial (abstr). Gastroenterology 2005; 128: A689.

266. Sandborn W, Rachmilewitz D, Hanauer S, Lichtenstein GR. De Villiers WJ, Olson A, Johanns J, Travers S, Colombel J-F. Infliximab induction and maintenance therapy for ulcerative colitis: The Act 2 trial (abstr). Gastroenterology 2005; 128 (Suppl. 2): A688.

267. Jarnerot G, Hertervig E, Friis-Liby I, Blomquist L, Karlen P, Granno C, Vilien M, Strom M, Danielsson A, Verbaan H, Hell-strom PM, Magnuson A, Curman B. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: A randomized, placebo-controlled study. Gastroenterology 2005; 128: 1805-11.

268. Probert CS, Hearing SD, Schreiber S, Kuhbacher T, Ghosh S, Arnott ID, Forbes A. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: A randomised controlled trial. Gut 2003; 52: 998-1002.

269. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJS, Present D, Sands BE, Colombel JF. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462-76.

270. Herfarth H, Obermeier F, Andus T, Rogler G, Nikolaus S, Kuehbacher T, Schreiber S. Improvement of arthritis and arthralgia after treatment with infliximab (Remicade) in a German prospective, open label, multicenter trial in refractory Crohn’s disease. Am J Gastroenterol 2002; 97: 2688-90.

271. Rutgeerts P, Van Assche G, Vermeire S. Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology 2004; 126: 1593-610.

272. Bowie VL, Snella KA, Gopalachar AS, Bharadwaj P. Listeria meningitis associated with infliximab. Ann Pharmacother 2004; 38: 58-61.

273. Colombel JF, Loftus EV Jr, Tremaine WJ, Egan LJ, Harmsen WS, Schleck CD, Zinsmeister AR, Sandborn WJ. The safety profile of infliximab in patients with Crohn’s disease: The Mayo clinic experience in 500 patients. Gastroenterology 2004; 126: 19-31.

274. Ljung T, Karlen P, Schmidt D, Hellstrom PM, Lapidus A, Janc-zewska I, Sjoqvist U, Lofberg R. Infliximab in inflammatory bowel disease: Clinical outcome in a population based cohort from Stockholm County. Gut 2004; 53: 849-53.

275. Lichtenstein G, Cohen R, Feagan B, Sandborn WJ, Salzberg BA, Chen DM, Diamond RH. Safety of infliximab in Crohn’s disease: Data from the 5000-patients TREAT Registry (abstr). Gastroenterology 2004; 126: A54.

276. Gardam MA, Keystone EC, Menzies R, Manners S, Skamene E, Long R, Vinh DC. Antitumour necrosis factor agents and tuberculosis risk: Mechanisms of action and clinical management. Lancet Infect Dis 2003; 3: 148-55.

277. Mow WS, Abreu-Martin MT, Papadakis KA, Pitchon HE, Targan SR, Vasiliauskas EA. High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy. Clin Gastroenterol Hepatol 2004; 2: 309-13.

278. American Thoracic Society, CDC, and Infectious Diseases Society of America. Treatment of tuberculosis. MMWR Morb Mortal Wkly Rep 2003; 52(RR-11): 1-80.

279. Cheifetz A, Smedley M, Martin S, Reiter M, Leone G, Mayer L, Plevy S. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol 2003; 98: 1315-24.

280. Sandborn WJ, Hanauer SB. Infliximab in the treatment of Crohn’s disease: A user’s guide for clinicians. Am J Gastroenterol 2002; 97: 2962-72.

281. Vermeire S, Noman M, Van Assche G, Baert F, Van Steen K, Esters N, Joossens S, Bossuyt X, Rutgeerts P. Autoimmunity associated with anti tumor necrosis factor alpha treatment in Crohn’s disease: A prospective cohort study. Gastroenterology 2003; 125: 32-9.

282. Klapman JB, Ene-Stroescu D, Becker MA, Hanauer SB. A lupus like syndrome associated with infliximab therapy. Inflamm Bowel Dis 2003; 9: 176-8.

283. Bernstein CN, Blanchard JF, Kliewer E, Wajda A. Cancer risk in patients with inflammatory bowel disease: A population-based study. Cancer 2001; 91: 854-62.

284. Greenstein AJ, Gennuso R, Sachar DB, Heimann T, Smith H, Janowitz HD, Aufses AH Jr. Extraintestinal cancers in inflammatory bowel disease. Cancer 1985; 56: 2914-21.

285. Lewis JD, Bilker WB, Brensinger C, Deren JJ, Vaughn DJ, Strom BL. Inflammatory bowel disease is not associated with an increased risk of lymphoma. Gastroenterology 2001; 121: 1080-7.

286. Gyde SN, Prior P, Macartney JC, Thompson H, Waterhouse JA, Allan RN. Malignancy in Crohn’s disease. Gut 1980; 21: 1024-9.

287. Ekbom A, Helmick C, Zack M, Adami HO. Extracolonic malignancies in inflammatory bowel disease. Cancer 1991; 67: 2015-19.

288. Persson PG, Karlen P, Bernell O, Leijonmarck CE, Brostrom O, Ahlbom A, Hellers G. Crohn’s disease and cancer: A population based cohort study. Gastroenterology 1994; 107: 1675-9.

289. FDA Board Document. Update on the TNF-alpha blocking agent; 2003. Available at: FDA Board Document. SAFETY OF TNF BLOCKING AGENTS. Accessed Feb 13, 2006. www.fda.gov/ohrms/dockets/ac/03/briefing/3930B1_01_B-TNF.Briefing. htm.

290. Lichtenstein GR, Cohen R, Feagan B, Sandborn WJ, Salzberg BA, Chen D, Pritchard M, Diamond RH. Safety of infliximab and other Crohn’s disease therapies-updated TREAT Registry data with over 10,000 patient-years of follow-up (abstr). Gastroenterology 2005; 128: A-580.

291. Jess T, Winther KV, Munkholm P, Langholz E, Binder V. Mortality and causes of death in Crohn’s disease: follow-up of a population based cohort in Copenhagen County, Denmark. Gastroenterology 2002; 122: 1808-14.

292. Loftus EV, Jr., Silverstein MD, Sandborn WJ, Tremaine WJ, Harmsen WS, Zinsmeister AR. Crohn’s disease in Olmsted County, Minnesota, 1940-93: Incidence, prevalence, and survival. Gastroenterology 1998; 114: 1161-8.

293. Farmer RG, Whelan G, Fazio VW. Longterm follow up of patients with Crohn’s disease. Relationship between the clinical pattern and prognosis. Gastroenterology 1985; 88: 1818-25.

294. Ekbom A, Helmick CG, Zack M, Holmberg L, Adami HO. Survival and causes of death in patients with inflammatory bowel disease: A population based study. Gastroenterology 1992; 103: 954-60.

295. Schwartz DA, Wiersema MJ, Dudiak KM, Fletcher JG, Clain JE, Tremaine WJ, Zinsmeister AR, Norton ID, Boardman LA, Devine RM, Wolff BG, Young-Fadok TM, Diehl NN, Pemberton JH, Sand-born WJ. A comparison of endoscopic ultrasound, magnetic resonance imaging, and exam under anesthesia for evaluation of Crohn’s perianal fistulas. Gastroenterology 2001; 121: 1064-72.

296. Talbot C, Sagar PM, Johnston MJ, Finan PJ, Burke D. Infliximab in the surgical management of complex fistulating anal Crohn’s disease. Colorectal Dis 2005; 7: 164-8.

297. Regueiro M, Valentine J, Plevy S, Fleisher MR, Lichtenstein GR. Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease. Am J Gastroenterol 2003; 98: 1821-6.

298. Kugathasan S, Miranda A, Nocton J, Drolet BA, Raasch C, Binion DG. Dermatologic manifestations of Crohn disease in children: response to infliximab. J Pediatr Gastroenterol Nutr 2003; 37: 150-4.

299. Rispo A, Lembo G, Insabato L, Cozzolino A, Pesce G, Castiglione F. Successful treatment of therapy resistant metastatic Crohn’s disease with infliximab. Br J Dermatol 2004; 150: 1045-6.

300. Benitez-Del-Castillo JM, Martinez-De-La-Casa JM, Pato-Cour E, Méndez-Fernández R, López-Abad C, Matilla M, García-Sánchez J. Long-term treatment of refractory posterior uveitis with anti-TNF alpha (infliximab). Eye 2005; 19: 841-5.

301. Murphy CC, Ayliffe WH, Booth A, Makanjuola D, Andrews PA, Jayne D. Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis. Ophthalmology 2004; 111: 352-6.

302. Temekonidis TI, Alamanos Y, Nikas SN, Bougias DV, Georgiadis AN, Voulgari PV, Drosos AA. Infliximab therapy in patients with ankylosing spondylitis: an open label 12 month study. Ann Rheum Dis 2003; 62: 1218-20.

303. Lupascu A, Armuzzi A, De Pascalis B, Carloni E, Lauritano EC, Gasbarrini A, Pola P, Gasbarrini A. Sacroileitis and peripheral arthropathy associated with ulcerative colitis: effect of infliximab on both articular and intestinal symptoms. Dig Liver Dis 2004; 36: 423-5.

304. Kaufman I, Caspi D, Yeshurun D, Dotan I, Yaron M, Elkayam O. The effect of infliximab on extraintestinal manifestations of Crohn’s disease. Rheumatol Int 2005; 25: 406-10.

305. Freeman HJ, Davis JE, Prest ME, Lawson EJ. Granulomatous bronchiolitis with necrobiotic pulmonary nodules in Crohn’s disease. Can J Gastroenterol 2004; 18: 687-90.

306. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT. Randomized, double-blind, placebo controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003; 107: 3133-40.

307. Mohan N, Edwards ET, Cupps TR, Oliverio PJ, Sandberg G, Crayton H, Richert JR, Siegel JN. Demyelination occurring during antitumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 2001; 44: 2862-2869.

308. Nanavati SA, Ergun GA, Schwartz JT. Avoiding infliximab in the treatment of Crohn’s disease in patients with multiple sclerosis. Am J Gastroenterol 2003; 98: 2333-34.

309. Thomas CW Jr, Weinshenker BG, Sandborn WJ. Demyelination during antitumor necrosis factor alpha therapy with infliximab for Crohn’s disease. Inflamm Bowel Dis 2004; 10: 28-31.

310. Strong BY, Erny BC, Herzenberg H, Razzeca KJ. Retrobulbar optic neuritis associated with infliximab in a patient with Crohn disease. Ann Intern Med 2004; 140: W34.

311. Mejico LJ. Infliximab-associated retrobulbar optic neuritis. Arch Ophthalmol 2004; 122: 793-4.

312. Sandborn WJ, Loftus EV. Balancing the risks and benefits of infliximab in the treatment of inflammatory bowel disease. Gut 2004; 53: 780-2.

313. Tremaine WJ, Hanauer SB, Katz S, Winston BD, Levine JG, Persson T, Persson A; Budesonide CIR United States Study Group. Budesonide CIR capsules (once or twice daily divided-dose) in active Crohn’s disease: A randomized placebo controlled study in the United States. Am J Gastroenterol 2002; 97: 1748-54.

314. Entocort EC [package insert]. Wayne, PA: AstraZeneca Pharmaceuticals; 2005.

315. Bouhnik Y, Lemann M, Mary JY, Scemama G, Tai R, Matuchansky C, Modigliani R, Rambaud JC. Long-term follow up of patients with Crohn’s disease treated with azathioprine or 6-mercaptopurine. Lancet 1996; 347: 215-19.